Bayer/Onyx Submit Nexavar sNDA For Liver Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Filing is based on halted Phase III trial showing overall survival of 44 percent in patients with hepatocellular carcinoma treated with sorafenib.